Resilience
3115 Merryfield Row, Suite 200
San Diego, CA 92121
T: (888) 737-2460
E: contact@resilience.com
LinkedIn: https://www.linkedin.com/company/weareresilience
Twitter: https://twitter.com/incresilience
W: https://resilience.com

READ OUR LATEST WHITEPAPER – The Stage-Gate Model: A Proven Approach to Streamline Biomanufacturing

 

COMPANY DESCRIPTION

Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines across a variety of therapeutic areas. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions.

COMPANY BACKGROUND

Resilience is leading the pursuit of novel medicines and all large molecule drugs by revolutionizing how they are developed and manufactured.

The technology of manufacturing complex medicines hasn’t kept pace with the wave of scientific discoveries fueling them over the past three decades.

Additionally, Resilience has collaborated with numerous institutions, including Mayo Clinic, MD Anderson Cancer Center and Harvard University, to seek to accelerate innovation in the creation of impactful therapies and technologies to benefit patients.

MARKETS SERVED/FACILITIES

Resilience serves global customers through its sites located in six states across the U.S., as well as in Canada.

PRODUCTS, SERVICES & CAPABILITIES

With more than 50 active customers across its network, ranging from large pharma to small and mid-size pharmaceutical and biotechnology companies, as well as government and NGOs, Resilience works across all stages of five primary modalities: Biologics, Vaccines, Nucleic Acids, Cell Therapy and Gene Therapy. Resilience offers several ways to engage, including incubation, collaboration and manufacturing to support the development of more than 70 molecules across its portfolio. The company’s offerings include Platform Technology & Development, Process &
Analytical Development and Clinical & Commercial Manufacturing, geared toward increasing access to medicines around the world and democratizing manufacturing.